This week in therapeutics




Licensing status

Publication and contact information


Breast cancer

Neurokinin 1 substance P (TAC1; NK1); NK1 substance P receptor (TACR1); HER2 (EGFR2; ErbB2; neu)

Studies in cell culture and mice suggest antagonizing NK1 or TACR1 could be useful for treating HER2+ breast cancer. In cultured tumor cells, NK1 increased HER2 signaling compared with vehicle. In cell culture and mouse xenografts, a small molecule TACR1 antagonist decreased HER2 signaling and tumor growth compared with saline control. Next steps include comparing the effects of TACR1 inhibitors and anti-NK1 mAbs in mouse models of breast cancer.
Merck & Co. Inc. markets the TACR1 antagonist Emend fosaprepitant dimeglumine to prevent chemotherapy-induced nausea and vomiting (CINV).
At least eight other TACR1 antagonists are in preclinical through Phase III testing for various neurological indications (see HER2's outside help, page 10).

SciBX 6(40); doi:10.1038/scibx.2013.1121
Published online Oct. 17, 2013

Patented in EU; available for licensing

Garcia-Recio, S. et al. Cancer Res.; published online Sept. 12, 2013;
Contact: Vanessa Almendro, Hospital Clinic of Barcelona, Barcelona, Spain